Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990912892> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2990912892 endingPage "vi285" @default.
- W2990912892 startingPage "vi285" @default.
- W2990912892 abstract "Abstract BACKGROUND Between 1995 and 2002 the EORTC Brain Tumor Group conducted a prospective phase III study on adjuvant procarbazine, CCNU and vincristine (PCV) chemotherapy in anaplastic oligodendroglioma (AOD). A mature follow-up presented in 2012 showed survival benefit of the addition of PCV, in particular in 1p/19q co-deleted tumors and tumors with MGMT promoter methylation. We now present very long term follow-up. MATERIALS AND METHODS Patients were eligible if locally diagnosed with a newly diagnosed AOD. They were randomized between radiotherapy (RT, 33 x 1.8 Gy) and the same RT followed by 6 cycles PCV (RT/PCV). Primary endpoints were overall survival (OS) and progression free survival (PFS). 1p/19q status (FISH) was determined in 300 patient. Kaplan- Meier technique and Cox modeling were used for long term survival analysis. Primary analyses were adjusted for known prognostic factors. For other analyses no adjustment was performed. RESULTS With 368 patients included, a median follow-up of 18.4 years and 307 (83%) survival events, median and 20-year survival after RT/PCV versus RT alone were 42.3 mo and 16.8% vs 30.6 months and 10.1% (HR 0.78; 95% CI (0.63, 0.98), adjusted p=0.06). Eighty patients were 1p/19q codel of which 26 (33%) were still alive, in this subgroup median and 20-year survival after RT/PCV versus RT alone were 14 years and 37.1% versus 9.3 years and 13.6% (HR 0.60, 95% CI (0.35, 1.03), unadjusted p=0.06). Twenty year PFS in 1p/19q codel was 31.3% in RT/PCV treated patients and 10.8% in RT only treated patients (HR 0.49, 95% CI (0.29, 0.83), unadjusted p=0.007). In the 1p/19q codel subgroup age, WHO PS and necrosis at pathology were identified to be of independent prognostic value for OS. CONCLUSION This long term analysis confirms the earlier conclusions and provides data on long term survival in this patient group. In 1p/19q codel patients treated with RT/PCV, the 20-year PFS and OS rates are 31% and 37% respectively." @default.
- W2990912892 created "2019-12-05" @default.
- W2990912892 creator A5001307415 @default.
- W2990912892 creator A5005487497 @default.
- W2990912892 creator A5011185863 @default.
- W2990912892 creator A5017177249 @default.
- W2990912892 creator A5020867751 @default.
- W2990912892 creator A5022651335 @default.
- W2990912892 creator A5026805885 @default.
- W2990912892 creator A5027716902 @default.
- W2990912892 creator A5037395192 @default.
- W2990912892 creator A5038129366 @default.
- W2990912892 creator A5039803490 @default.
- W2990912892 creator A5039870067 @default.
- W2990912892 creator A5045074679 @default.
- W2990912892 creator A5056837393 @default.
- W2990912892 creator A5075152654 @default.
- W2990912892 creator A5086283695 @default.
- W2990912892 creator A5087336206 @default.
- W2990912892 date "2019-11-01" @default.
- W2990912892 modified "2023-10-16" @default.
- W2990912892 title "LTBK-12. EORTC 26951, RANDOMIZED STUDY OF ADJUVANT PCV AFTER 59.4 GY RADIOTHERAPY: VERY LONG TERM FOLLOW-UP" @default.
- W2990912892 doi "https://doi.org/10.1093/neuonc/noz219.1201" @default.
- W2990912892 hasPublicationYear "2019" @default.
- W2990912892 type Work @default.
- W2990912892 sameAs 2990912892 @default.
- W2990912892 citedByCount "2" @default.
- W2990912892 countsByYear W29909128922022 @default.
- W2990912892 crossrefType "journal-article" @default.
- W2990912892 hasAuthorship W2990912892A5001307415 @default.
- W2990912892 hasAuthorship W2990912892A5005487497 @default.
- W2990912892 hasAuthorship W2990912892A5011185863 @default.
- W2990912892 hasAuthorship W2990912892A5017177249 @default.
- W2990912892 hasAuthorship W2990912892A5020867751 @default.
- W2990912892 hasAuthorship W2990912892A5022651335 @default.
- W2990912892 hasAuthorship W2990912892A5026805885 @default.
- W2990912892 hasAuthorship W2990912892A5027716902 @default.
- W2990912892 hasAuthorship W2990912892A5037395192 @default.
- W2990912892 hasAuthorship W2990912892A5038129366 @default.
- W2990912892 hasAuthorship W2990912892A5039803490 @default.
- W2990912892 hasAuthorship W2990912892A5039870067 @default.
- W2990912892 hasAuthorship W2990912892A5045074679 @default.
- W2990912892 hasAuthorship W2990912892A5056837393 @default.
- W2990912892 hasAuthorship W2990912892A5075152654 @default.
- W2990912892 hasAuthorship W2990912892A5086283695 @default.
- W2990912892 hasAuthorship W2990912892A5087336206 @default.
- W2990912892 hasBestOaLocation W29909128921 @default.
- W2990912892 hasConcept C10515644 @default.
- W2990912892 hasConcept C126322002 @default.
- W2990912892 hasConcept C143998085 @default.
- W2990912892 hasConcept C2776694085 @default.
- W2990912892 hasConcept C2776755627 @default.
- W2990912892 hasConcept C2777389519 @default.
- W2990912892 hasConcept C2779112685 @default.
- W2990912892 hasConcept C2779429289 @default.
- W2990912892 hasConcept C2779434656 @default.
- W2990912892 hasConcept C2780739268 @default.
- W2990912892 hasConcept C3019894029 @default.
- W2990912892 hasConcept C50382708 @default.
- W2990912892 hasConcept C509974204 @default.
- W2990912892 hasConcept C71924100 @default.
- W2990912892 hasConcept C90924648 @default.
- W2990912892 hasConceptScore W2990912892C10515644 @default.
- W2990912892 hasConceptScore W2990912892C126322002 @default.
- W2990912892 hasConceptScore W2990912892C143998085 @default.
- W2990912892 hasConceptScore W2990912892C2776694085 @default.
- W2990912892 hasConceptScore W2990912892C2776755627 @default.
- W2990912892 hasConceptScore W2990912892C2777389519 @default.
- W2990912892 hasConceptScore W2990912892C2779112685 @default.
- W2990912892 hasConceptScore W2990912892C2779429289 @default.
- W2990912892 hasConceptScore W2990912892C2779434656 @default.
- W2990912892 hasConceptScore W2990912892C2780739268 @default.
- W2990912892 hasConceptScore W2990912892C3019894029 @default.
- W2990912892 hasConceptScore W2990912892C50382708 @default.
- W2990912892 hasConceptScore W2990912892C509974204 @default.
- W2990912892 hasConceptScore W2990912892C71924100 @default.
- W2990912892 hasConceptScore W2990912892C90924648 @default.
- W2990912892 hasIssue "Supplement_6" @default.
- W2990912892 hasLocation W29909128921 @default.
- W2990912892 hasLocation W29909128922 @default.
- W2990912892 hasOpenAccess W2990912892 @default.
- W2990912892 hasPrimaryLocation W29909128921 @default.
- W2990912892 hasRelatedWork W1988089466 @default.
- W2990912892 hasRelatedWork W2001918395 @default.
- W2990912892 hasRelatedWork W2104071976 @default.
- W2990912892 hasRelatedWork W2105229005 @default.
- W2990912892 hasRelatedWork W2123453386 @default.
- W2990912892 hasRelatedWork W2127591066 @default.
- W2990912892 hasRelatedWork W2149477053 @default.
- W2990912892 hasRelatedWork W2339196520 @default.
- W2990912892 hasRelatedWork W2413791266 @default.
- W2990912892 hasRelatedWork W2990912892 @default.
- W2990912892 hasVolume "21" @default.
- W2990912892 isParatext "false" @default.
- W2990912892 isRetracted "false" @default.
- W2990912892 magId "2990912892" @default.
- W2990912892 workType "article" @default.